IVX 0.00% 0.3¢ invion limited

potential partners in the biosphere, page-6

  1. 1,072 Posts.
    lightbulb Created with Sketch. 126
    "
    Professor Bond made a similar discovery previously with a particular class of beta blockers with regards to the treatment of chronic heart failure, for which beta blockers were con- traindicated. He brought that discovery to Dr Mitchell Glass (now Invion’s Chief Medical Officer) at GlaxoSmithKline. That subset of drugs became the best drugs ever available to decreasing mortality in heart failure, according to Professor Bond. The discovery moved a $40 million selling drug in 1998 to a $1.5 billion dollar drug in 2010.

    For the second time Professor Bond has sought to commercialise his work on contraindications of beta blockers through Dr Mitchell Glass, this time through Invion.
    "
    Bioshares
 
watchlist Created with Sketch. Add IVX (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $19.81M
Open High Low Value Volume
0.4¢ 0.4¢ 0.3¢ $15.39K 4.899M

Buyers (Bids)

No. Vol. Price($)
32 19778023 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 2194077 7
View Market Depth
Last trade - 16.10pm 02/08/2024 (20 minute delay) ?
IVX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.